Keywords
adipose tissue
pathogenesis of obesity
How to Cite
Abstract
Obesity is defined as excess of fat deposits. To quantify excess of adipose tissue the use of certain instruments not routinely utilized is required, e.g. magnetic resonance or by means of fat dual-energy absorptiometry aimed to obtain a more specific definition. Instead, the most commonly used obesity assessment is the body mass index, BMI, which shows ratio between weight in kg. over height in m². BMI limit in adults is considered to be 25 kg/m²; it is accepted as obesity in adults a BMI ? 30 Kg/m²; BMI among 25 and 30 Kg/m² means overweight. Obesity degree may be grouped in class 1, BMI between 30 and ? 35; class 2, BMI be- tween 35 and ? 40; and class 3, BMI over 40(1). BMI adjustments for children and gender are necessary.
MBI meets the needs to estimate adipocytes mass at population levels and define susceptibility to the several complications obesity poses. Nevertheless, it is not of use to define individual obesity degree, due to variations of skeletal muscle and other components of lean tissue. Excess of muscle tissue among athletes of people who practice athletic sports may cause BMI error.
In the majority of endocrine sicknesses effective treatments are available, based on knowledge of mechanisms producing alteration. Such is not the case of obesity, of which we have little knowledge on its pathogenesis, despite decades of research and the millions of dollars spent on its treatment every year. Interest for the study of this entity and its treatment is due to the fact that 1/3 of adults in the USA suffer from this problem(3-7).
References
2. Bray G, Battle of the Bulge: A History of Obesity Research. Philadelphia, PA Dorrance Publishing 2007.
3. Cohen PA, Maller G, DeSouza R, et al. Presence of banned drug in dietary supplement following FDA recalls. JAMA. 2014; 312:1691-1693.
4. Schwartz TB, Henry Harrowen and the turbulent begging of endocrinology. Ann Intern Med. 1999; 131: 702-706.
5. Schwartz MW. Can the history of modern endocrinology shape the future of obesity? Mol Endocrinol. 2015; 29: 155-157.
6. Cushing H. Disorders of the pituitary gland. Retrospective and prophetic. JAMA. 1921; 76: 172-1726.
7. Norberg M, Lindwall K, Jenking PL, et al. Self-rated health does not predict 10-year weight change among middle-aged adults: a longitudinal population study. 13 MC Public Health. 2011; 11: 248.
8. Key A. Human starvation and its consequence. JAMA Diet Assoc. 1946; 22: 582-587.
9. Leibel RL, Rosenbaum M, Hirsch J, et al. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995; 332:621-628.
10. Butryn ML, Webb V, Wadden TA. Behavioral treatment of obesity. Psychiatry Clin North Am. 2011; 34: 841-859.
11. Alamuddin N, Wadden TA. Behavioral treatment of the patient with obesity. Endocrinal Metab Clin North Am. 2016; 45:565.580.
12. Pasquet P, Apfelbaum M. Recovery of initial body weight and composition after long-term massive overfeeding in men. Am J Clin Nutr. 1994; 60: 861-863.
13. Diaz EO, Prentice AM, Goldberg GR, et al. Metabolic response to experimental overfeeding in lean and overweight healthy volunteers. Am J Clin Nutr. 1992; 56: 641-655.
14. Rosenbaum M, Leibel RL. Physiological adaptation following weight reduction. In Brownell KD, Walsh BT, eds. Eating Disorders and Obesity. A comprensive Handbook, 3rd New York, NY. Guilford Press.
15. Flier JS, Clinical review 94. What is in a home? In research of leptin´s physiology role. J Clin endocrinol Metab. 1998; 83: 1407-1413.
16. Faroogi IS, Jebb SA, Lang mack G, Metab. Effect of recombinant leptin therapy in a child with deficiency. N Engl J Med. 1999; 341: 1879-884.
17. Faroogi IS, O´Rahilly S. Monogenic human obesity syndromes. Recent Prog Horm Res. 2004: 59; 409-424.
18. Myers MG, Jr, Heymsfield SB, et al. Challenges and opportunities of defining clinic leptin resistance. Cell Metab. 2012; 15: 150-156.br />19. Myers MG, Jr. Leptin keeps working even in obesity. Cell Metab. 2015;21:791-792.
20. Leibel RL. The role of leptin on the control of body weight. Nutr Rev. 2002;60: 515-519.
21. Schwartz W, Randy J, Seely, et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocrine Rev. 2017; 38 (4): 267-296.
22. Muolo DM, Dohn GL, Fiedorek FT, Jr, et al. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes. 1997; 46: 360-363.
23. Voshol PJ, Jong MC, Dahlmans VE, et al. In muscle specific lipoprotein lipase- overexpressing mice, muscle triglyceride content is increased without inhibition of insulin stimulated whole body and muscle specific glucose uptake. Diabetes. 2001; 50: 2585- 2590.
24. Shimada M, Shimano H, Gotoda T, et al. Over expression of human lipoprotein lipase in transgenic mice. J Biol Chem. 1993; 297: E271- E288.
25. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Phisiol Endocrinol Metab. 2009; 297: E271-E288.
26. Amemiya A, Bean LJH, Bird T, et al. Gene reviews (Internet), Seattle WA; University of Washington. 1993- 2017. 1999. Oct 12 (updated 2011).
27. Ludwig DS, Friedman MI. Increasing adiposity; consequence or cause of overeating. JAMA 2014; 311: 2167-2168.
28. Hall KD, Chen KY, Guo J, et al. Energy expenditure and body composition changes after an isocalorie ketogenic diet in overweight and obese men. Am J Clin Nutr. 2016; 104 (2): 324-333.
29. Kennedy GC. The hypothalamus and obesity. Proc R Soc. Med. 1966; 59:1276-1277.
30. Soley RI, Berridge KC. The hunger games. Cell 2015; 160:805-806.
31. Boden G, Chen X, Mozzoli M, et al. Effect of fasting on serum leptin in normal humans subjects. J Clin Endocrinol Metab. 1996; 81: 1419- 1423.
32. Krashes MI, Koda S, Ye C, et al. Rapid reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Inves. 2011: 1424- 1428.
33. Schwartz MW, Seely RJ, Woods SC, et al. Leptin increase hypothalamic pro-opio melanocortin m RNA expression in the rostral arcuate nucleus. Diabetes. 1997; 46: 2119-2123.
34. Xu Y, Jones JE, Lauzon DA, et al. A serotonin and melanocortin circuit mediates o-fenfluramine anorexia. J Neurosci. 2010; 30: 1430-1434.
35. Burdge GC, Lillycrop KA, Philips ES, et al. Folic acid supplementation during the juvenile pubertal period in rats modifies the phenotype and epigenotype induced by prenatal nutrition. J Nutr. 2009; 139: 1054- 1060.
36. Gore AC, Chappel VA, Fenton SE. Endocrine Society´s Second Scientific Statement on endocrine disrupting chemicals. Endocrine Rev. 2015; 36: E1- E150.
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent. A copy may be reviewed here